Silver Book Fact

1 in 3 people will develop shingles

An estimated 1 in 3 people will develop shingles in their lifetime.

Harpaz, Rafael, Ismael R. Ortega-Sanchez, and Jane F. Seward. Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Report. 2008; 57(RR-5): 1-30

Reference

Title
Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Publication
MMWR Recomm Report
Publication Date
2008
Authors
Harpaz, Rafael, Ismael R. Ortega-Sanchez, and Jane F. Seward
Volume & Issue
Volume 57, Issue RR-5
Pages
1-30

Categories

  • Cost of Disease
  • Prevalence & Incidence

Related Facts

  • Drug-resistant MRSA expensive to treat
    As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.  
  • Pneumonia leading cause of death and infection
    Community-acquired pneumonia was the #6 cause of death and the #1 cause of death from infection in the U.S. in 2003.  
  • Vaccine-eligible account for majority of shingles-related hospitalizations
    The shingles vaccine-eligible population (i.e., persons aged 60 years or older) accounted for 74% of the total annual shingles-related hospital charges in 2004.  
  • Mortality from vaccine-preventable diseases
    Vaccine-preventable diseases or their complications account for 50,000 to 90,000 adult deaths in the U.S. each year.  
  • Shingles pain occurs in ~50% of cases in older adults
    Complications of shingles—including postherpetic neuralgia (PHN)—occur in almost 50 percent of older persons with the disease.